YANTAI, China, March 10, 2024 /PRNewswire/ — RemeGen Co. Ltd.(“RemeGen” or “the Company”) (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently gave an oral presentation on an interim analysis of the evaluation of the Company’s proprietary Disitamab Vedotin (RC48), an…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.